ACIU Overview

Interim Results from VacSYn Trial: AC Immune SA reported promising interim safety and efficacy results from its Phase 2 VacSYn trial for the anti-alpha-synuclein immunotherapy ACI-7104.056, indicating potential slowing of Parkinson's disease progression through stabilization of disease-related biomarkers.

Robust Antibody Response: The treatment induced a strong antibody response against the target antigen, with a 100% responder rate and significantly higher antibody levels in both serum and cerebrospinal fluid compared to the placebo group.

Clinical Measures of Stabilization: Clinical assessments showed that the ACI-7104.056 group did not experience meaningful progression in motor symptoms, contrasting with the expected increase in the placebo group, suggesting a trend toward disease stabilization.

Future Expectations: The trial results are generally safe and well-tolerated, with final data from Part 1 of the VacSYn trial anticipated in mid-2026, while AC Immune's stock saw a notable increase following the announcement.

Positive Trial Results: AC Immune SA announced positive interim results from the Phase 2 VacSYn trial of ACI-7104.056, showing a 100% responder rate in antibody response against alpha-synuclein in early Parkinson's disease.

Potential Disease Modification: The trial indicated stabilization of disease-relevant biomarkers, suggesting a potential slowing of Parkinson's disease pathology and highlighting the treatment's efficacy and safety.

Regulatory Plans: Following these findings, AC Immune plans to seek regulatory feedback on the clinical development plan for ACI-7104.056.

Market Impact: AC Immune's stock closed at $2.54, reflecting an 8.63% decline on the Nasdaq following the announcement.

Positive Trial Results: AC Immune's stock rose ~30% after announcing positive initial results from a mid-stage trial for ACI-7104.056, an immunotherapy for early Parkinson’s disease, which met all target criteria for immunogenicity in a placebo-controlled study.

Safety and Efficacy: The therapy was reported to be generally safe and well-tolerated, with interim data suggesting it could slow the progression of Parkinson's disease by targeting alpha-synuclein pathology.

Regulatory Plans: AC Immune plans to meet with regulatory authorities to discuss accelerating the drug's development towards registration, with final data from the trial expected in mid-2026.

Trial Details: The Phase 2 VacSYn trial involved 34 patients who received at least 12 months of treatment, marking a significant step in the development of immunotherapy for Parkinson's disease.